Oncolytic intralesional therapy for metastatic melanoma.

Autor: DePalo DK; Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive Room 4123, Tampa, FL, USA., Perez MC; Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive Room 4123, Tampa, FL, USA., Huibers A; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden., Olofsson Bagge R; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden., Zager JS; Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive Room 4123, Tampa, FL, USA. jonathan.zager@moffitt.org.; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. jonathan.zager@moffitt.org.
Jazyk: angličtina
Zdroj: Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Aug; Vol. 41 (4), pp. 457-460. Date of Electronic Publication: 2023 Aug 09.
DOI: 10.1007/s10585-023-10228-4
Abstrakt: In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therapies are one category of non-surgical treatment options available for ITM. They induce tumor cell lysis and systemic anti-tumor activity through selective infection of tumor cells by naturally occurring or genetically modified factors. While there are numerous oncolytic viral therapies in various stages of development for the treatment of ITM, this discussion focuses on the mechanism and available literature for the two most established herpes virus-based therapies.
(© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: